Common Questions in Anticoagulation Management in Atrial Fibrillation.
The limitations of the vitamin K antagonists (VKAs) have promoted the development of novel oral anticoagulants (NOACs) to benefit patients with poor predicted anticoagulation control. To assess the probability of good or poor anticoagulation control with VKAs, the SAMe-TT2R2 score has been developed. Trials of stroke prevention have shown a significant reduction in hemorrhagic stroke and intracranial bleeding with the NOACs. Clinicians need to be prepared to manage bleeding complications and patients requiring urgent surgery, systemic thrombolysis for ischemic stroke, or ST elevation myocardial infarction. This article addresses some of these management issues.